BCAX Bicara Therapeutics Inc. Insider Trading

BCAX CEO Mazumdar sells 36.8K shares for $704.7K at $19.17; stock -0.8% from 52-week high but +32.8% in 30 days

Mazumdar, as Chief Executive Officer of Bicara Therapeutics, divested 36,766 shares for $704,657.16 at $19.17 on 2026-03-09, reducing holdings by 9.8% to 339,392 shares. The sale occurred near the 52-week high ($20.06), with the current price of $19.90 only 0.8% below that peak, while the stock has surged 32.8% over the past 30 days and 5.6% over 90 days. Notably, Mazumdar's cross-ticker track record shows a 100% well-timed rate across 1 prior sell (with a 90-day return of -17.9%), and this most recent sale at BCAX represents his second transaction at this ticker following a prior sell on 2025-11-24 that also showed negative 90-day returns. Against this backdrop, the company reported a net loss of $36.3M over its most recent full fiscal year, operating at an unprofitable level with a $1.1B market cap. The timing of the sale—executed at a price near historical highs following a sharp 30-day rally—in the context of sustained operating losses, suggests the insider found current valuations appropriate for partial exit.

RA Capital Management (Director) acquired 300,000 shares of BCAX at $16.00 for $4.8M, bringing total holdings to 4.60M shares

RA Capital Management purchased 300,000 shares at $16.00, expanding its position by 7.0% to 4.60M shares. The acquisition occurred when BCAX trades at $17.59, 8.0% below its 52-week high of $19.11 and reflecting a 4.7% gain over the prior 30 days. This is material given RA Capital's scale as a director-level stakeholder. However, contextual signals are mixed: Bicara is unprofitable with a net income of -$36.3M over its most recent full fiscal year, which limits the comfort level of the buy. Across RA Capital's full cross-ticker open-market history, prior buys averaged a 30-day return of 53.2%, but its prior sells have been poorly timed (average 90-day return +3.5% and well-timed rate 0.00%), suggesting mixed predictive skill. This transaction adds data but does not constitute sufficient evidence of exceptional conviction at BCAX specifically.

CEO Claire Mazumdar sold 41,163 shares of BCAX at $18.86 on 2025-11-24 (41.2K shares, $776.4K); holds 309,892 shares post-transaction.

Claire Mazumdar, Chief Executive Officer of Bicara Therapeutics, sold 41,163 shares valued at $776,428.85, reducing her stake by 11.7% from 351,055 to 309,892 shares. This sale occurred at $18.86 per share while the company trades at $18.46 and remains significantly unprofitable with a net loss of $36,330,000.00 for its most recent fiscal year. The timing of the sale—at the higher end of the 52-week range and after a 53.6% run-up over 90 days—reflects a material reduction in the CEO's ownership concentration. Despite substantial remaining holdings at 309,892 shares, the nature and magnitude of this sale warrant monitoring given the company's loss position and the execution context.

CFO Ivan Hyep sold 30,385 shares in 3 transactions for $553,198.15 at BCAX, reducing stake 17.3% during 46.5% rally

CFO Ivan Hyep executed 3 separate sales totaling 30,385 shares between October 6–8, 2025, at blended average price $18.21, realizing $553,198.15 and reducing his holdings from 175,740 to 145,355 shares. The sales occurred during a period of significant upward momentum (30-day change: +46.5%; 90-day change: +81.4%) and while the stock remains -28.5% below its 52-week high of $25.19. The timing of this substantial reduction warrants attention given that Bicara remains unprofitable (net income: $-27,388,000.00) and the company's $982,131,138.00 market cap is supported largely by recovery sentiment rather than demonstrated earnings. Without visibility into whether these sales are structured (e.g., 10b5-1 plan) or discretionary, the concurrent reduction in insider equity stake and the scale of the disposal merit investor scrutiny of underlying business conditions.

COO Ryan Cohlhepp sold 50,500 shares at $18.06 across 4 transactions for $911,841.99

Ryan Cohlhepp, President and COO of Bicara Therapeutics, executed 4 separate sales totaling 50,500 shares for $911,841.99, reducing his holdings from 253.1K shares to 202.6K shares (-19.9%). The company is unprofitable with net income of $-27,388,000.00 over its most recent full fiscal year. The stock has risen 81.4% over 90 days and 46.5% over 30 days, trading at $18.00 near the midpoint of its 52-week range ($8.71–$25.19). The sale by a C-level executive during a period of significant stock appreciation in an unprofitable company warrants monitoring of broader insider activity and forward guidance.

CLO Lara Meisner liquidates entire stake: 79,146 shares sold for $1,021,210.80 (Mar 14, 2025)

Chief Legal Officer Lara Meisner sold all 79,146 shares of her holdings through 2 separate sales on 2025-03-14, exiting her position entirely. The sales were executed at $12.69 and $13.24 per share, yielding a blended average price of $12.90, at a time when the stock is trading 54.0% below its 52-week high of $27.07 and down 23.9% over the past 90 days. A complete stake liquidation by the company's top legal officer, combined with the stock's significant drawdown from recent highs and the company's negative net income of $-17,481,000.00, warrants investor attention to underlying company fundamentals and potential legal or operational developments.

RA Capital Management acquired 1,833,000 shares at $18.00 (IPO price) for $32,994,000; post-transaction holdings: 2,652,575 shares

RA Capital Management, a director at Bicara Therapeutics, executed 2 separate purchases totaling 1,833,000 shares at $18.00 on 2024-09-16 for $32,994,000, adding 223.7% to its prior 819,575-share stake. The transaction occurred at the IPO offering price on the first day of trading (BCAX listed 4 trading days ago), and the company's current market price of $25.73 reflects post-IPO appreciation. As a director with substantial equity stake expansion at IPO pricing, this represents a meaningful signal of insider confidence in the company's foundational valuation; however, the derivative-conversion flag indicates the director's full economic position extends beyond the Form 4 Table I shares shown and requires cross-referencing Table II data for complete position context.

Flynn James E (10% Owner) acquires 70,000 shares for $1,260,000.00 in 2 transactions at $18.00; holdings rise to 897,587 shares

10% owner Flynn James E purchased 70,000 shares in two separate $630,000 tranches on 2024-09-17 at $18.00 per share, increasing total holdings by 8.5% to 897,587 shares post-transaction. The purchase occurred at a price $9.07 below the current market price of $27.07 (as of filing date), suggesting the transaction executed during the early trading period following the recent listing (3 trading days old). Note: this filing contains derivative conversion activity whose full details reside in Form 4 Table II and are not yet populated in our database; the reported Table I position should not be interpreted as the insider's complete holdings. The magnitude of the acquisition and the timing relative to the company's recent public emergence merit tracking, though interpretation is constrained by the absence of historical trading patterns at this ticker and the limited public price history available.